LXRX — Lexicon Pharmaceuticals, Inc. stock price, charts and financials

QT78Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
2.45
-0.02-0.74%
OverviewShort InterestFilings
LXRXQT78Lexicon Pharmaceuticals, Inc.·NASDAQ
2.45-0.74%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.52%$15.45MESO+4.71%$16.69ZBIO-0.93%$32.13GHRS-1.77%$29.73TSHA-1.59%$6.46STOK-1.28%$32.29ABCL+38.89%$9.63VRDN-3.05%$22.87
Snapshot
Index-P/E-EPS (ttm)-0.07Insider Own-Shs Outstand444.20MPerf Week6.93%
Market Cap1.10BForward P/E-EPS next Y-0.20Insider Trans0.10%Shs Float214.31MPerf Month9.78%
Enterprise Value1.06BPEG0.13EPS next Q-Inst Own-Short Float7.37%Perf Quarter47.02%
Income-61.99MP/S26.46EPS this Y-126.66%Inst Trans-Short Ratio10.06Perf Half Y109.32%
Sales41.47MP/B6.19EPS next Y-24.97%ROA-24.44%Short Interest32.73MPerf YTD114.78%
Book/sh-P/C-EPS next 5Y-ROE-40.40%52W High2.66 -7.84%Perf Year114.78%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-23.16%52W Low1.01 142.16%Perf 3Y30.69%
Dividend Est.-EV/EBITDA-Sales past 3/5Y- 15.81%Gross Margin98.85%Volatility9.25% 6.96%Perf 5Y-30.23%
Dividend TTM-EV/Sales25.47EPS Y/Y TTM88.89%Oper. Margin-131.43%ATR (14)0.17Perf 10Y-84.99%
Dividend Ex-Date-Quick Ratio13.29Sales Y/Y TTM122.58%Profit Margin-147.38%RSI (14)59.05Recom2.79
Dividend Gr. 3/5Y-Current Ratio13.37EPS Q/Q96.29%SMA206.67%Beta1.02Target Price6.00
Payout0.00%Debt/Eq0.00Sales Q/Q2000.00%SMA5012.04%Rel Volume0.88Prev Close2.47
Employees81LT Debt/Eq0.52EarningsNov 05SMA20045.68%Avg Volume3.52MPrice2.45
IPO DateApr 07, 2000Option/ShortNo / YesEPS/Sales Surpr.92.45% 115.55%Net Debt/EBITDA0.78Volume3,085,740Change-0.74%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-12-26ReiteratedH.C. WainwrightBuy$6.00
Mar-04-25DowngradeLeerink PartnersOutperform → Market Perform
Oct-18-24ReiteratedLeerink Partners$6.00
Jan-29-21UpgradeJP MorganUnderweight → Neutral
Jan-29-21DowngradeWedbushOutperform → Neutral
Dec-08-20UpgradeCitigroupNeutral → Buy
Nov-18-20UpgradeGabelli & Co.Hold → Buy
Dec-11-19DowngradeGabelli & Co.Buy → Hold
Nov-08-19DowngradeCitigroupBuy → Neutral
Sep-11-19UpgradeGabelli & Co.Hold → Buy
Latest News
Aug-06-26
Aug-06-2605:05PM
Lexicon Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
01:47PM
Lexicon Pharmaceuticals (NASDAQ:LXRX) Falls as Q2 Revenue Misses EstimatesChartMill
01:34PM
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcriptseekingalpha.com
10:51AM
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimateszacks.com
07:30AM
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updatesglobenewswire.com
Jul-30-26
Jul-30-2608:30AM
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026globenewswire.com
Jul-27-26
Jul-27-2608:35AM
Lexicon Pharmaceuticals Completes Randomization Of Patients In Its Pivotal Phase 3 'Sotagliflozin In Patients With Symptomatic Obstructive And Non-Obstructive Hypertrophic Cardiomyopathy' Clinical TrialBenzinga
08:30AM
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)globenewswire.com
Jul-08-26
Jul-08-2609:30AM
Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% RallyChartMill
Company

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue415031——————
Cost of Goods Sold Incl. D&A001——————
Gross Profit415030——————
Selling, General and Administrative Excl. Other3637132——————
Research and Development606184——————
Other Operating Expense-1012——————
Operating Income-55-49-197——————
Interest Expense9816——————
Unusual Expense
—————————
Non-Operating Income (Expense)2712——————
Net Income Before Taxes-62-50-200——————
Income Taxes
000——————
Consolidated Net Income-62-50-200——————
Net Income From Continuing Operations-62-50-200——————
Net Income-62-50-200——————
EPS (Recurring)-0.15-0.14-0.63——————
EPS (Basic, Before Extraordinaries)-0.15-0.14-0.63——————
EPS (Diluted)-0.15-0.14-0.63——————
EBITDA-51-41-184——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio26.198.357.62——————
Gross Margin100.00100.0096.77——————
Operating Margin-134.15-98.00-635.48——————
Net Margin-151.22-100.00-645.16——————
Shares Outstanding438363320——————
Market Capitalization1,074417236——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$2.94$2.29$1.63$0.97$0.32● Close Price0.00M0.68M1.36M2.04M2.72MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Swain Judith LDirectorJun 03 '26Option Exercise0.0089,3120174,486Jun 04
Sullivan Diane E.DirectorJun 03 '26Option Exercise0.0089,3120126,122Jun 04
SOBECKI CHRISTOPHER JDirectorJun 03 '26Option Exercise0.0089,3120293,177Jun 04
Cheung IvanDirectorJun 03 '26Option Exercise0.0089,312089,312Jun 04
BARKER SAM LDirectorJun 03 '26Option Exercise0.0089,3120213,771Jun 04
Amouyal PhilippeDirectorJun 03 '26Option Exercise0.0089,3120374,486Jun 04
DEBBANE RAYMONDDirectorJun 03 '26Option Exercise0.0089,31201,995,498Jun 04
Artal Participations S.a r.l.director, 10 percent owner:Apr 30 '26Option Exercise0.0020,830,1700175,156,062May 08
McDermott WendySVP, Human ResourcesFeb 28 '26Option Exercise0.00224,4060346,052Mar 03
Martens Rachel YapSVP, Partnerships & Corp StratFeb 28 '26Option Exercise0.0067,090067,090Mar 03
Granowitz Craig BSVP, Chief Medical OfficerFeb 28 '26Option Exercise0.00312,2760432,528Mar 03
Gopinathan SumaSVP, DiscoveryFeb 28 '26Option Exercise0.0099,9500174,470Mar 03
DeFrancesco LisaSVP, IR and Corp CommFeb 28 '26Option Exercise0.00152,8640168,441Mar 03
Crum Brian TSVP, General Counsel & Secr.Feb 28 '26Option Exercise0.00273,0060533,821Mar 03
Coiante Scott MSVP, Chief Financial OfficerFeb 28 '26Option Exercise0.00160,2370160,237Mar 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.